Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 2 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Line item | Parmaneti | GNG Pharma | Akhali Khedva | Iberi + | Iberiparma + |
|---|---|---|---|---|---|
| Total Current Assets | 1,061 | 1,243 | — | — | — |
| Total Non-Current Assets | 1,235 | 125 | — | — | — |
| TOTAL ASSETS | 2,296 | 1,368 | — | — | — |
| Total Current Liabilities | 632 | 819 | — | — | — |
| Total Non-Current Liabilities | 569 | 0 | — | — | — |
| TOTAL LIABILITIES | 1,201 | 819 | — | — | — |
| Total Equity | 1,095 | 549 | — | — | — |
| Balance Check (Assets - L&E) | 0 | 0 | — | — | — |
| Total Debt | 781 | 0 | — | — | — |
| Cash & Equivalents | 49 | 127 | — | — | — |
| Net Debt | 732 | -127 | — | — | — |
Not every picked company reports every selected year — FY2024: 3 of 5 companies have no filing. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Parmaneti | Pharma | 5.7% | 25th pct | 110 |
| GNG Pharma | Pharma | 4.1% | 20th pct | 110 |
| Akhali Khedva | Pharma | — | no FY data | 110 |
| Iberi + | Pharma | — | no FY data | 110 |
| Iberiparma + | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.